Drug Trial Radar · NCT05727839
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Feb 24, 2023
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Immorna Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors
Conditions
- Cutaneous Tumor
- Malignant Solid Tumor
Interventions
JCXH-211 InjectionDrug
JCXH-211 administered once every 28 days or 14days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicityTime frame: Within 28 days or 14days after the first dose
- Incidence of adverse events (Safety and Tolerability)Time frame: From consent to 28 days after the last dose of study drug
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
The George Washington Medical Faculty Associates
Washington D.C., District of Columbia
Sun Yat-sen University Cancer Center
Guangdong, Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.